EMPOWER YOUR RESEARCH

## Product datasheet for AM39013RP-N

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

## CD15 Mouse Monoclonal Antibody [Clone ID: BRA-4F1]

## Product data:

Product Type: Primary Antibodies

Clone Name:
Applications:
BRA-4F1
FC, IF
Recommended Dilution:
Suitable for studies of activated T cells, analysis of myeloid leukemias, myeloid differentiation and identification of Reed-Sternberg cells in subtypes of Hodgkin's disease.

- Flow cytometry: for analysis of blood and bone marrow samples. The reagent is effectively formulated for direct immunofluorescent staining (see "Protocols" below).
- Immunofluorescence: using cytospots or frozen tissue sections.

| Reactivity: | Human |
| :--- | :--- |
| Host: | Mouse |
| Isotype: | $\operatorname{IgM}$ |

Clonality:
Specificity:

Formulation:

Purification:
Conjugation:
Storage:

Stability:

Monoclonal
Clone BRA-4F1 is specific for the Lewis $x$ antigen. It does not cross react with the sialylated form of CD15.
0.01 M sodium phosphate, $0.15 \mathrm{M} \mathrm{NaCl}, \mathrm{pH} 7.3,0.2 \% \mathrm{BSA}, 0.09 \%$ sodium azide Label: PE
State: Liquid purified Ig fraction
Label: (R-Phycoerythrin)
Affinity chromatography
PE
Store the antibody undiluted at $2-8^{\circ} \mathrm{C}$.
This product is photosensitive and should be protected from light.
Shelf life: one year from despatch.

Background:

Synonyms:
Note:

CD15 is expressed on neutrophils, eosinophils and monocytes, but not on platelets, erythrocytes, normal B and T cells. It is also present in embryonic tissues and adenocarcinomas, myeloid leukemias and Reed-Sternberg cells [1,2].
CD15 antibodies recognize the terminal trisaccharide structure which is also referred to as the Lewis $x$ antigen. This structure is found on a variety of glycoproteins and glycolipids at the cell surface $[3,4]$. CD15 antibodies have been shown to affect a number of cell activities, but it is difficult to distinguish between effects on the CD15 structure itself and effects mediated by proteins which happen to carry the CD15 epitope. CD15 antibodies can mediate complement activation and may have potential therapeutic value in the killing of CD15-expressing tumor cells [2].

Lewis X, X-Hapten, Lacto-N-Fucopentaose III, Stage-Specific Embryonic Antigen, SSEA1

1. Conjugates with brighter fluorochromes, like PE and APC, will have a greater separation than those with dyes like FITC. When populations overlap, the percentage of positive cells using a selected marker can be affected by the choice of fluorescent label.
2. Use of monoclonal antibodies in patient treatment can interfere with antigen target recognition by this reagent. This should be taken into account when samples are analyzed from patients treated in this fashion.
3. Reagent data performance is based on EDTA-treated blood. Reagent performance can be affected by the use of other anticoagulants.

Protocol: Flow cytometry method for use with labeled (FITC, R-PE, APC, PerCP or PerCP-Cy5.5) monoclonal antibodies

1. Add $100 \mu \mathrm{l}$ of EDTA-treated blood (i.e. approx. 10 e 6 leukocytes) to a 5 ml reagent tube. The content of one tube is sufficient to perform one test.
2. Add to each tube $10 \mu \mathrm{l}$ of labeled monoclonal antibody. Vortex the tube to ensure thorough mixing of antibody and cells.
3. Incubate the tube for 15 minutes at room temperature in the dark.
4. Add $100 \mu$ l of a lyse reagent.
5. Incubate for 10 minutes at room temperature in the dark.
6. Add 2 ml of demineralized water and incubate for 10 minutes in the dark.
7. Centrifuge the labeled cell suspension for 2 minutes at $1000 \times \mathrm{g}$.
8. Remove the supernatant and resuspend the cells in $200 \mu \mathrm{l}$ of PBS.
9. Analyze by flow cytometry within four hours (alternatively, the cells may be fixed by $0.05 \%$ of formaline in buffered saline for analysis the next day. Some antigens are readily destroyed upon fixation and this should be taken into account when using this alternative).

## Flow cytometry method for use with dual and triple combinations

1. Add $100 \mu \mathrm{l}$ of EDTA-treated blood (i.e. approx. 10 e 6 leukocytes) to a 5 ml reagent tube. The content of one tube is sufficient to perform one test.
For combinations with anti-kappa and/or anti-lambda Ig seeApplication note below.
2. Add to each tube $20 \mu$ l of labeled monoclonal antibody combination.
(Appropriate mouse Ig isotype control samples should always be included in any labeling
study).
3. Vortex the tube to ensure thorough mixing of antibody and cells.
4. Incubate the tube for 15 minutes at room temperature in the dark.
5. Add $100 \mu \mathrm{l}$ of a lyse reagent and mix immediately.
6. Incubate for 10 minutes at room temperature in the dark.
7. Add 2 ml of demineralized water and incubate for 10 minutes in the dark.
8. Centrifuge the labeled cell suspension for 2 minutes at $1000 \times \mathrm{g}$.
9. Remove the supernatant and resuspend the cells in $200 \mu$ l of PBS.
10. Analyze by flow cytometry within four hours (alternatively, the cells may be fixed by $0.05 \%$ of formaline in buffered saline for analysis the next day. Some antigens are readily destroyed upon fixation and this should be taken into account when using this alternative).

## Application note for anti-kappa and/or anti-lambda Ig combinations

Add 2 ml of PBS containing $0.001 \%(\mathrm{v} / \mathrm{v})$ Heparin (prewarmed to $37^{\circ} \mathrm{C}$ ) to the cell suspension Vortex, centrifuge ( 2 min at 300 xg ) and discard the supernatant.
Repeat this step twice.
Resuspend the pelleted blood cells in $100 \mu \mathrm{l}$ PBS, pH 7.2, containing $0.001 \%$ (v/v) Heparin.

